



Tykerb® (lapatinib) – First-time generic

- On September 30, 2020, [Lupin launched](#) an [AB-rated](#) generic version of Novartis' [Tykerb \(lapatinib\)](#) tablets.
- Tykerb is approved in combination with:
 - [Capecitabine](#) for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab
 - [Letrozole](#) for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated.
- Tykerb carries a boxed warning for hepatotoxicity.
- According to IQVIA, Tykerb had annual sales of approximately \$61 million as of June 2020.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.